Multiple drugbinding sites on the R482G isoform of the ABCG2 transporter

No abstract is available for this paper.

• Publication year

  2006

• Venue

  British Journal of Pharmacology

• Publication date

  2006-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/sj.bjp.0706904PMID 16981002PMCID PMC2014674
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer

  2006influential reference
• Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues.

  2006influential reference
• Role of ABCG2 as a biomarker for predicting resistance to CPT‐11/SN‐38 in lung cancer

  2006influential reference
• Allosteric Modulation of Binding Properties between Units of Chemokine Receptor Homo- and Hetero-Oligomers

  2006cited by this paper
• Purification and 3D structural analysis of oligomeric human multidrug transporter ABCG2.

  2006cited by this paper
• Pharmacogenomics of the human ABC transporter ABCG2: from functional evaluation to drug molecular design

  2005cited by this paper
• The Topography of Transmembrane Segment Six Is Altered during the Catalytic Cycle of P-glycoprotein*

  2004cited by this paper
• Breast Cancer Resistance Protein and P-Glycoprotein in 149 Adult Acute Myeloid Leukemias

  2004cited by this paper
• Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome.

  2004cited by this paper
• Topoisomerase I inhibitors in the treatment of gastrointestinal cancer: from intravenous to oral administration.

  2004cited by this paper
• Order changes within receptor systems upon ligand binding: receptor tightening/oligomerisation and the interpretation of binding parameters.

  2004cited by this paper
• Mouse liver PMP70 and ALDP: homomeric interactions prevail in vivo.

  2004cited by this paper
• Mutational analysis of ABCG2: role of the GXXXG motif.

  2004cited by this paper
• Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump.

  2004cited by this paper
• Characterization of Oligomeric Human Half-ABC Transporter ATP-binding Cassette G2*

  2004cited by this paper
• Imatinib mesylate ( STI 571 ) is a substrate for the breast cancer resistance protein ( BCRP ) / ABCG 2 drug pump

  2004cited by this paper
• ABCG2 – a transporter for all seasons

  2004cited by this paper
• The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability.

  2004cited by this paper
• The role of ABC transporters in clinical practice.

  2003cited by this paper
• Structure–activity relationship: analyses of p‐glycoprotein substrates and inhibitors

  2003cited by this paper
• A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport.

  2003influential reference
• ABCG5 and ABCG8 Are Obligate Heterodimers for Protein Trafficking and Biliary Cholesterol Excretion*

  2003cited by this paper
• Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport.

  2003cited by this paper
• Use of peptide antibodies to probe for the mitoxantrone resistance-associated protein MXR/BCRP/ABCP/ABCG2.

  2002cited by this paper
• Dominant‐negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S‐S dependent homodimerization

  2002cited by this paper
• Multidrug resistance and cancer: the role of the human ABC transporter ABCG2.

  2002cited by this paper
• Characterization of Drug Transport, ATP Hydrolysis, and Nucleotide Trapping by the Human ABCG2 Multidrug Transporter

  2002cited by this paper
• A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance.

  2002cited by this paper
• Multidrug resistance in cancer: role of ATP–dependent transporters

  2002cited by this paper
• Frequent expression of the multi‐drug resistance‐associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP‐21 monoclonal antibody in paraffin‐embedded material

  2002cited by this paper
• Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells.

  2001influential reference
• Detailed characterization of cysteine‐less P‐glycoprotein reveals subtle pharmacological differences in function from wild‐type protein

  2001cited by this paper
• A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2).

  2001influential reference
• Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells.

  2001influential reference
• Communication between multiple drug binding sites on P-glycoprotein.

  2000cited by this paper
• The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia.

  2000cited by this paper
• P-Glycoprotein Levels Predict Poor Outcome in Patients With Osteosarcoma

  2000cited by this paper
• The homodimeric ATP‐binding cassette transporter LmrA mediates multidrug transport by an alternating two‐site (two‐cylinder engine) mechanism

  2000cited by this paper
• Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes.

  1999influential reference
• The molecular interaction of the high affinity reversal agent XR9576 with P‐glycoprotein

  1999cited by this paper
• A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance.

  1998influential reference
• Herpes Simplex Virus Inhibitor ICP47 Destabilizes the Transporter Associated with Antigen Processing (TAP) Heterodimer*

  1998cited by this paper
• Negative Cooperativity in the Human Bradykinin B2Receptor*

  1998cited by this paper
• A multidrug resistance transporter from human MCF-7 breast cancer cells.

  1998cited by this paper
• Both P-glycoprotein Nucleotide-binding Sites Are Catalytically Active (*)

  1995cited by this paper
• P-glycoprotein Is Stably Inhibited by Vanadate-induced Trapping of Nucleotide at a Single Catalytic Site (*)

  1995cited by this paper
• Pharmacologic analysis of drug-receptor interaction

  1994cited by this paper
• Characterization of the adenosine triphosphatase activity of Chinese hamster P-glycoprotein.

  1993cited by this paper
• P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma.

  1991cited by this paper
• A Pharmacologic Analysis of Drug-Receptor Interaction

  1987cited by this paper
• Molecular pharmacology of the calcium channel

  1984cited by this paper
• Molecular pharmacology of the calcium channel: evidence for subtypes, multiple drug-receptor sites, channel subunits, and the development of a radioiodinated 1,4-dihydropyridine calcium channel label, [125I]iodipine.

  1984cited by this paper
• The kinetics of competitive radioligand binding predicted by the law of mass action.

  1984cited by this paper
• Quantitative analysis of drug-receptor interactions: I. Determination of kinetic and equilibrium properties.

  1981cited by this paper

• Exploring the effect of intracellular loop 1 genetic variants in human ABCG2 on transport activity and protein abundance.

  2025cites this paper
• A time-resolved Förster resonance energy transfer assay to investigate drug and inhibitor binding to ABCG2.

  2024cites this paper
• A time-resolved Förster resonance energy transfer assay to investigate inhibitor binding to ABCG2

  2023cites this paper
• ABCB1 and ABCG2 Regulation at the Blood-Brain Barrier: Potential New Targets to Improve Brain Drug Delivery

  2023cites this paper
• Biochemical interactions between the Atm1-like transporter from Novosphingobium aromaticivorans and heavy metals

  2023cites this paper
• Intracellular Metabolomics Identifies Efflux Transporter Inhibitors in a Routine Caco-2 Cell Permeability Assay—Biological Implications

  2022cites this paper
• Advances in the application of fluorescence correlation spectroscopy to study detergent purified and encapsulated membrane proteins.

  2022cites this paper
• Analysis of Sequence Divergence in Mammalian ABCGs Predicts a Structural Network of Residues That Underlies Functional Divergence

  2021cites this paper
• Overexpression of ABCG2 Confers Resistance to MLN7243, a Ubiquitin-Activating Enzyme (UAE) Inhibitor

  2021cites this paper
• Identification of chemosensitizers by drug repurposing to enhance the efficacy of cancer therapy

  2020cites this paper
• The ABCG2/BCRP transporter and its variants – from structure to pathology

  2020cites this paper
• The transport pathway in the ABCG2 protein and its regulation revealed by molecular dynamics simulations

  2020cites this paper
• Picky ABCG5/G8 and promiscuous ABCG2 ‐ a tale of fatty diets and drug toxicity

  2020cites this paper
• The role of ABCG2 in modulating responses to anti-cancer photodynamic therapy.

  2020cites this paper
• Efflux transporters in cancer resistance: Molecular and functional characterization of breast cancer resistance protein

  2020cites this paper
• Overexpression of ABCG2 confers resistance to pevonedistat, an NAE inhibitor.

  2020cites this paper
• Application of fluorescence correlation spectroscopy to study substrate binding in styrene maleic acid lipid copolymer encapsulated ABCG2

  2020cites this paper
• ABCG2 requires a single aromatic amino acid to “clamp” substrates and inhibitors into the binding pocket

  2020cites this paper
• 3D structure of the transporter ABCG2—What's new?

  2020cites this paper
• ABCG2 transports anticancer drugs via a closed-to-open switch

  2020cites this paper
• Role of transporters in drug disposition and drug-drug interactions

  2020cites this paper
• Synthesis and biological evaluation of quinazoline derivatives - A SAR study of novel inhibitors of ABCG2.

  2019cites this paper
• Evaluation of inhibitory effects of flavonoids on breast cancer resistance protein (BCRP): From library screening to biological evaluation to structure-activity relationship.

  2019cites this paper
• Papel del transportador ABCG2/BCRP y sus polimorfismos en la secreción activa de compuestos a leche y su modulación a través de compuestos naturales en rumiantes

  2019cites this paper
• ABCG2: does resolving its structure elucidate the mechanism?

  2018cites this paper
• Residues contributing to drug transport by ABCG2 are localised to multiple drug-binding pockets

  2018cites this paper
• How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance?

  2018cites this paper
• Optimizing the flavanone core toward new selective nitrogen-containing modulators of ABC transporters.

  2018cites this paper
• Polymorphisms of the Multidrug Pump ABCG2: A Systematic Review of Their Effect on Protein Expression, Function, and Drug Pharmacokinetics

  2018cites this paper
• Characterization of toxicologically significant efflux transporters and their interactions with drugs

  2018cites this paper
• A Screening Strategy for Evaluation of Drug Transport across the Blood-Brain Barrier: Application to Catechol-O-methyltransferase Inhibitors, Dopamine β-hydroxylase Inhibitors and Dibenz[b,f]azepine-5-carboxamide Derivatives

  2018cites this paper
• Structure-function relationships in ABCG2: insights from molecular dynamics simulations and molecular docking studies

  2017cites this paper
• The structure of the human ABC transporter ABCG2 reveals a novel mechanism for drug extrusion

  2017cites this paper
• Nature et conséquences des interactions entre transporteurs membranaires et pesticides

  2017cites this paper
• Synthesis and biological investigation of 2,4-substituted quinazolines as highly potent inhibitors of breast cancer resistance protein (ABCG2).

  2017cites this paper
• PharmGKB summary: very important pharmacogene information for ABCG2

  2017cites this paper
• Dual Modulation of Human P-Glycoprotein and ABCG2 with Prodrug Dimers of the Atypical Antipsychotic Agent Paliperidone in a Model of the Blood-Brain Barrier.

  2017cites this paper
• Development and Validation of a Computational Model Ensemble for the Early Detection of BCRP/ABCG2 Substrates during the Drug Design Stage

  2017cites this paper
• The multidrug transporter ABCG2: still more questions than answers

  2016cites this paper
• The multidrug transporter ABCG 2 : still more questions than answers

  2016cites this paper
• Plasma membrane dynamics and tetrameric organisation of ABCG2 transporters in mammalian cells revealed by single particle imaging techniques.

  2016cites this paper
• Identification of residues in ABCG2 affecting protein trafficking and drug transport, using co-evolutionary analysis of ABCG sequences

  2015cites this paper
• Providing a molecular mechanism for P-glycoprotein; why would I bother?

  2015cites this paper
• Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transport—an Update

  2014cites this paper
• Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics

  2014cites this paper
• Structure and function of BCRP, a broad specificity transporter of xenobiotics and endobiotics

  2014cites this paper
• Interaction of the Efflux Transporters ABCB1 and ABCG2 With Imatinib, Nilotinib, and Dasatinib

  2014cites this paper
• Determinants of the activity and substrate recognition of breast cancer resistance protein (ABCG2)

  2014cites this paper
• High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4).

  2014cites this paper
• A female gametocyte-specific ABC transporter plays a role in lipid metabolism in the malaria parasite

  2014cites this paper
• Baicalein decreases side population proportion via inhibition of ABCG2 in multiple myeloma cell line RPMI 8226 in vitro.

  2014cites this paper
• Towards understanding promiscuity in multidrug efflux pumps.

  2014cites this paper
• Heterologous expression of membrane proteins in Saccharomyces cerevisiae

  2014cites this paper
• New insights into the role of breast cancer resistance protein in endocrine and metabolic processes

  2014cites this paper
• Synthesis and ABCG2 inhibitory activity of novel fumitremorgin C analogs--specificity and structure activity correlations.

  2013cites this paper
• Fluorescent substrates for flow cytometric evaluation of efflux inhibition in ABCB1, ABCC1, and ABCG2 transporters.

  2013cites this paper
• Reversal of ABCG2-mediated multidrug resistance by human cathelicidin and its analogs in cancer cells.

  2013cites this paper
• Breast cancer resistance protein (BCRP)/ABCG2

  2013cites this paper
• Interactions of the Multidrug Resistance Modulators Tariquidar and Elacridar and their Analogues with P‐glycoprotein

  2013cites this paper
• Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2.

  2013cites this paper
• Diferencias interespecíficas y polimórficas en la actividad y modulación a través de inhibidores del transportador ABCG2/BCRP = Interspecific and polymorphic differences in the activity and modulation mediated by inhibitors of the ABCG2/BCRP transporter

  2013cites this paper
• Flavonoids and Drug Interactions

  2012cites this paper
• Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein.

  2012cites this paper
• Antibody binding shift assay for rapid screening of drug interactions with the human ABCG2 multidrug transporter.

  2012cites this paper
• 8.8 Molecular Aspects of the Translocation Process by ABC Proteins

  2012cites this paper
• 4-Substituted-2-phenylquinazolines as inhibitors of BCRP.

  2012cites this paper
• The ABCG family of membrane‐associated transporters: you don't have to be big to be mighty

  2011influential citation
• Plant Compounds and Derivatives as Inhibitors of Cancer Cell Multidrug Resistance

  2011cites this paper
• Identification of proline residues in or near the transmembrane helices of the human breast cancer resistance protein (BCRP/ABCG2) that are important for transport activity and substrate specificity.

  2011cites this paper
• pH-Dependent Transport of Pemetrexed by Breast Cancer Resistance Protein

  2011cites this paper
• ABC multidrug transporters: target for modulation of drug pharmacokinetics and drug-drug interactions.

  2011cites this paper
• Pre-Clinical and Clinical Investigation of Pharmacokinetic and Pharmacodynamic Interactions between Darunavir, a Novel Protease Inhibitor, and Rosuvastatin

  2011cites this paper
• Combined ligand- and structure-based studies on inhibitors of P-glycoprotein

  2011cites this paper
• BCRP (ABCG2) expression, function and regulation in model and intestinal epithelial cells

  2011cites this paper
• Dimerization of ABCG2 Analysed by Bimolecular Fluorescence Complementation

  2011cites this paper
• Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP).

  2011cites this paper
• Interactions of dietary phytochemicals with ABC transporters: possible implications for drug disposition and multidrug resistance in cancer

  2010cites this paper
• Novel lead for potent inhibitors of breast cancer resistance protein (BCRP).

  2010cites this paper
• Pharmacoinformatic approaches to design natural product type ligands of ABC-transporters.

  2010cites this paper
• Optimization of the Antitumor Activity of Sequence-specific Pyrrolobenzodiazepine Derivatives Based on their Affinity for ABC Transporters

  2010cites this paper
• Multidrug efflux pumps: The structures of prokaryotic ATP‐binding cassette transporter efflux pumps and implications for our understanding of eukaryotic P‐glycoproteins and homologues

  2010cites this paper
• Drug transport by breast cancer resistance protein

  2010cites this paper
• Modulation of the activity of ABC transporters (P-glycoprotein, MRP2, BCRP) by flavonoids and drug response.

  2010cites this paper
• Differential inhibition of murine Bcrp1/Abcg2 and human BCRP/ABCG2 by the mycotoxin fumitremorgin C.

  2010cites this paper
• Role of Basic Residues within or near the Predicted Transmembrane Helix 2 of the Human Breast Cancer Resistance Protein in Drug Transport

  2010cites this paper
• JPET #163493 1 Role of Basic Residues Within or Near the Predicted Transmembrane Helix 2 of the Human Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transport

  2010cites this paper
• Structure and function of the human breast cancer resistance protein (BCRP/ABCG2).

  2010cites this paper
• Drug-like property concepts in pharmaceutical design.

  2009cites this paper
• Natural Allelic Variants of Bovine ATP-Binding Cassette Transporter ABCG2: Increased Activity of the Ser581 Variant and Development of Tools for the Discovery of New ABCG2 Inhibitors

  2009cites this paper
• ABC efflux pump-based resistance to chemotherapy drugs.

  2009cites this paper
• Bile Canalicular Transporters

  2009cites this paper
• The blood-brain barrier thyroxine transporter organic anion-transporting polypeptide 1c1 displays atypical transport kinetics.

  2009cites this paper
• Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy.

  2009cites this paper
• Substrate-Dependent Breast Cancer Resistance Protein (Bcrp1/Abcg2)-Mediated Interactions: Consideration of Multiple Binding Sites in in Vitro Assay Design

  2009cites this paper
• Rational design of pyrrolobenzodiazepine derivatives

  2009cites this paper
• Structural Determinants of Imidazoacridinones Facilitating Antitumor Activity Are Crucial for Substrate Recognition by ABCG2

  2009cites this paper
• Purification and structural analyses of ABCG2.

  2009cites this paper
• Substrate dependent Abcg2/Bcrp1-mediated interactions: consideration of multiple binding sites in in vitro assay design

  2008cites this paper
• BCRP-Breast Cancer Resistance Protein

  2008cites this paper
• Exploring the possible interaction between anti-epilepsy drugs and multidrug efflux pumps; in vitro observations.

  2008cites this paper